Imv Inc (NYSE:IMV) – Stock analysts at B. Riley lowered their FY2019 earnings per share estimates for IMV in a research note issued to investors on Monday, November 11th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.36) per share for the year, down from their prior forecast of ($0.34). B. Riley also issued estimates for IMV’s FY2020 earnings at ($0.45) EPS, FY2021 earnings at ($0.65) EPS and FY2022 earnings at ($0.44) EPS.
IMV has been the subject of several other reports. Zacks Investment Research lowered IMV from a “hold” rating to a “sell” rating in a research report on Wednesday. Echelon Wealth Partners restated a “buy” rating and set a $12.25 price target on shares of IMV in a research report on Tuesday. Raymond James set a $10.00 price target on IMV and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Co assumed coverage on IMV in a research report on Monday, October 28th. They set a “market perform” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $11.50 price target on shares of IMV in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. IMV presently has an average rating of “Buy” and an average target price of $9.60.
IMV (NYSE:IMV) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.03). The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.05 million.
A number of large investors have recently added to or reduced their stakes in the stock. Hartford Financial Management Inc. boosted its holdings in IMV by 9.6% in the third quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock valued at $94,000 after purchasing an additional 3,348 shares during the period. Royal Bank of Canada boosted its holdings in IMV by 3.6% in the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock valued at $288,000 after purchasing an additional 3,453 shares during the period. Citadel Advisors LLC purchased a new position in IMV in the second quarter valued at $37,000. Bank of Montreal Can boosted its holdings in IMV by 17.5% in the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock valued at $260,000 after purchasing an additional 13,228 shares during the period. Finally, Morgan Stanley boosted its holdings in IMV by 260.5% in the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock valued at $264,000 after purchasing an additional 65,300 shares during the period.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.